AI-powered early detection of skin cancer using a smartphone
AI-Driven Early Detection of Skin Cancer
This project tests whether the NuvanaDx smartphone app can detect skin cancer, including melanoma, in adults who have suspicious skin lesions.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Months and up |
| Sex | All |
| Sponsor | Nuvana Healthcare LTD Industry-sponsored |
| Locations | 1 site (London) |
| Trial ID | NCT07144306 on ClinicalTrials.gov |
What this trial studies
The project will collect both retrospective and prospective anonymized photos of skin lesions plus related clinical data to validate an AI algorithm (NuvanaDx) against dermatology-confirmed diagnoses. Images will be captured by smartphones and reviewed centrally to determine the tool's sensitivity, specificity, and predictive values. The study intentionally includes diverse skin tones and populations to measure performance across groups. It will also gather user experience and workflow data to see how the app might fit into clinical triage and care pathways.
Who should consider this trial
Good fit: Adults (18 and older) with skin lesions that are suspicious for malignancy who can provide informed consent and submit usable smartphone images are the intended participants.
Not a fit: People who cannot give informed consent, those unable to produce good-quality photos, children, or patients whose lesions are not suitable for smartphone imaging are unlikely to benefit from this study.
Why it matters
Potential benefit: If successful, the tool could enable earlier detection and faster triage of suspicious skin lesions via smartphone, reducing wait times and improving access to dermatology care.
How similar studies have performed: Previous research has shown AI tools can detect skin cancer with promising accuracy but performance has varied by dataset and skin tone, so broader validation like this is still needed.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Adults (≥18 years) presenting with skin lesions suspicious for malignancy. Ability to provide informed consent. Exclusion Criteria: Inability to provide informed consent. Poor-quality images unsuitable for AI analysis.
Where this trial is running
London
- Nuvana Healthcare Ltd — London, United Kingdom (Recruiting)
Study contacts
- Study coordinator: Sushma Saxena, Director, Nuvana Healthcare Ltd
- Email: sushma.saxena@nuvana.co.uk
- Phone: +44 7481986525
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.